Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DARKFOX (alternative open reading frame of FOXM1) (DARKFOX)
- Target
- DARKFOX
- Molecular classification
- Polypeptide product of an alternative open reading frame (ORF) of FOXM1, Tumor antigen (HLA-presented peptide antigen), Cancer antigen
01
Overview
DARKFOX is a novel, cancer-specific antigen derived from an alternative open reading frame (ORF) of the FOXM1 gene, robustly expressed at the surface of multiple solid tumor cell types and minimally in normal cells. It is the founding member of a new class of 'Dark Antigens,' discovered by Enara Bio, and represents a highly tumor-specific and homogeneously expressed target suitable for immunotherapies including bispecific T cell engagers. ENA101 is a lead therapeutic developed to specifically target DARKFOX, demonstrating potent cytotoxicity and strong potential to transform care for patients with diverse, high-prevalence solid tumors.
02
Mechanism of action
T cell-mediated cytotoxicity via recognition of DARKFOX-derived HLA-presented peptide, activated by bispecific T cell engager (ENA101)
03
Biological functions
Tumor antigen presentationImmune recognition (by T cells)
04
Disease associations
CancerSolid malignancies (lung, breast, gastrointestinal, squamous cell carcinomas, head & neck, esophageal cancers)
05
Safety considerations
Potential off-tumor toxicity (minimized: DARKFOX described as having minimal expression in normal tissue)Immunogenicity of bispecific T cell engager
06
Interacting drugs
ENA101 (bispecific T cell engager targeting DARKFOX)
07
Biomarkers
Expression of DARKFOX in tumor tissue for patient selection (implied by its use as a target for T cell therapy)
Beyond the preview
Go deeper on DARKFOX (alternative open reading frame of FOXM1) (DARKFOX).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DARKFOX (alternative open reading frame of FOXM1) (DARKFOX).